Novo Nordisk and AWS Unite Agentic AI for Drug Discovery

Novo Nordisk is significantly deepening its engagement with Amazon Web Services (AWS), announcing a strategic partnership that will see the pharmaceutical giant leverage AWS’s artificial intelligence capabilities across its entire drug discovery pipeline. This collaboration, positioning AWS as Novo Nordisk’s preferred cloud provider and strategic AI partner, signals a pivotal moment in the application of advanced technology within the life sciences sector.

At the heart of this expanded alliance is the establishment of a co-innovation hub at Novo Nordisk’s London facility. This dedicated space will foster direct collaboration between AWS engineers, AI specialists, and applied scientists, and Novo Nordisk’s own research and development teams. The objective is to streamline critical research workflows, from initial target identification and therapeutic design to the meticulous analysis of vast biological datasets, thereby accelerating the often lengthy and complex journey from a molecule concept to a potential patient treatment.

Thilde Hummel Bøgebjerg, Executive Vice President of Enterprise IT & Quality at Novo Nordisk, emphasized the synergistic potential of this partnership. “AI has the potential to transform how we discover, develop, and deliver medicines, but real impact comes from combining advanced technology with deep scientific expertise and a clear focus on patients,” she stated. This sentiment underscores Novo Nordisk’s commitment to harnessing AI not just as a technological tool, but as a catalyst for meaningful patient outcomes.

AI Enhances and Accelerates Research Workflows

This new initiative builds upon Novo Nordisk’s existing sophisticated use of AWS technologies. The company has already seen substantial gains by implementing generative AI platforms, such as those built on Amazon Bedrock. An AWS case study highlighted that over 25,000 Novo Nordisk employees have utilized a generative AI platform to develop chatbots addressing more than 2,500 distinct use cases. These applications span non-regulated processes, including expedited information retrieval and automated document drafting, with one notable deployment processing over 26,000 prompts monthly across a corpus of 140,000 documents.

The impact of generative AI is particularly evident in clinical documentation. Novo Nordisk has reported that a system utilizing Anthropic’s Claude 3.5 through Amazon Bedrock dramatically reduced the time required for generating certain clinical documents, cutting it by over 90%. This efficiency gain is transformative: tasks that previously demanded 40 to 50 individuals and up to 15 weeks of work could now be accomplished by a team of three in mere minutes, with crucial oversight and validation by medical professionals remaining integral to the process.

The latest agreement pushes the application of generative AI deeper into the scientific core of drug research. A key component is Amazon Bio Discovery, a service engineered to empower computational biology and drug development through advanced AI models and intelligent agents. AWS states that Bio Discovery offers researchers access to over 40 biological AI models. These AI agents can autonomously select and orchestrate various models for specific research tasks, and organizations can also integrate their proprietary models with AWS-hosted solutions for complex, multi-step workflows.

Novo Nordisk intends to deploy Bio Discovery for critical functions such as identifying novel drug targets, designing innovative therapies, and conducting in-depth analysis of biological information. The platform’s capability to generate and rank potential drug candidates prior to their progression to laboratory synthesis and testing is a significant advancement. Crucially, experimental results can be fed back into the computational workflow, creating a continuous loop of analysis and refinement that tightly integrates computational drug design with physical experimentation.

Furthermore, Novo Nordisk will leverage Amazon Bedrock to build AI applications capable of processing and integrating diverse datasets, including clinical, genomic, and imaging data. This integration is expected to enable early-stage research findings to directly inform and shape the design of clinical trials, leading to more targeted and efficient trial protocols.

Novo Nordisk Broadens the Scope of AI Agents in Research

The partnership also encompasses Amazon Bedrock AgentCore, AWS’s robust infrastructure for the deployment and management of AI agents. AgentCore is designed to enable these agents to interact seamlessly with enterprise data, connect with existing systems, and execute complex, multi-step workflows autonomously. While Novo Nordisk has not disclosed the specific AgentCore functionalities it plans to implement in each research workflow, the company has signaled its intent to deploy this technology across a wide spectrum of research and operational processes.

Dan Sheeran, Vice President and General Manager of Healthcare and Life Sciences at AWS, highlighted the strategic focus on agentic AI in drug discovery. “Novo Nordisk’s partnership with AWS shows what’s possible when you pair AI with deep life-sciences expertise — removing bottlenecks across drug discovery, not just studying them,” he remarked. This underscores the shift from AI as an analytical tool to AI as an active participant in driving research forward.

This expanded collaboration represents a significant evolution from Novo Nordisk’s earlier deployments of Bedrock, which were primarily focused on employee-facing generative AI applications. The new agreement firmly integrates AWS AI tools into the core scientific and operational workflows that underpin drug development.

AWS CEO Matt Garman expressed enthusiasm for the potential of this alliance, stating that the companies aim to leverage these technologies to drastically shorten drug discovery timelines, efficiently process complex research datasets, and apply emergent findings across a broad range of therapeutic areas.

To facilitate this deep integration, AWS Forward Deployed Engineers will work directly alongside Novo Nordisk teams on the systems developed through this partnership. This program embeds AWS technical experts with clients to collaborate on ambitious AI projects, including the development of advanced agent-based applications.

This strategic alliance with AWS is part of a broader relationship between Novo Nordisk and Amazon, which also includes collaborations with Amazon Pharmacy, Amazon Ads, and One Medical. In parallel, AWS has recently announced similar AI collaborations within the life sciences sector with Flagship Pioneering and Johnson & Johnson.

Novo Nordisk’s commitment to advancing AI in its operations is not limited to this AWS partnership. The company has also engaged with OpenAI for AI deployments across drug discovery, manufacturing, and commercial operations. Furthermore, Novo Nordisk is utilizing Denmark’s Gefion supercomputer, a powerful resource for AI model development and other data-intensive scientific research.

Novo Nordisk CEO Mike Doustdar reiterated the overarching goal of the AWS partnership: to accelerate drug discovery and expand the strategic application of AI across the company’s critical work in chronic diseases, ultimately aiming to bring life-changing treatments to patients more rapidly.